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Vitamin K-dependent coagulation factors can promote adenoviral cell transduction in vitro. In vivo, warfarin
pretreatment ablates liver targeting of an adenovirus serotype 5 (Ad5) vector deleted of CAR binding capa-
bility. Here, we assess in vivo transduction and biodistribution of Ad5 vectors with nonmodified fibers (Ad5)
and a serotype 47 fiber-pseudotyped Ad5 (Ad5/47; subgroup D) virus following intravascular injection. War-
farin reduced liver transduction by both viruses. However, no impact on early liver virus accumulation was
observed, suggesting no effect on Kupffer cell interactions. Hence, coagulation factors play a pivotal role in
selectively mediating liver hepatocyte transduction of Ad5 and Ad5/47 vectors.
Adenovirus (Ad) vectors are commonly used biological tools
for in vitro and in vivo gene delivery. The route of Ad delivery
principally defines both the infectivity profile and the subse-
quent toxicity of the virus. The delivery of Ad via the intravas-
cular route is broadly appealing both for liver-directed gene
therapy (7, 13) and for targeting of nonhepatic tissues via
alternate receptors (5, 19). In the paradigm of intravascular
gene delivery, there is a complex yet poorly characterized pat-
tern of virus-host interactions, including those with blood cells
and plasma proteins. A fuller understanding of these interac-
tions is necessary for the development of safe and efficient
targeting to individual organs. Prior studies have demonstrated
Ad interactions with red blood cells (2, 12) and white blood
cells (9), as well as plasma proteins such as coagulation zymo-
gens and complement pathway components (15, 18, 23). Re-
cent evidence has shown a substantial role for coagulation
zymogens in the delivery of Ad to the liver following intravas-
cular injection (15, 18). This contrasts sharply with the ac-
cepted mechanism of Ad serotype 5 (Ad5) vector transduction
in vitro with tethering to the cell surface through the fiber knob
domain, which binds CAR (1, 21), and internalization through
the penton base, which engages v integrins (22). Potential
redundancy of CAR in Ad5-mediated transduction of the liver
is supported by studies showing little or no difference in liver
sequestration for CAR binding and non-CAR binding Ad (re-
viewed in reference 11). Anatomically, the distribution of CAR
expression is restricted to tight junctions (3); hence, the con-
siderable levels of hepatocyte transduction observed with sys-
temically administered Ad vectors would be difficult to recon-
cile with such restricted expression of CAR.
We recently documented a definitive role for plasma coag-
ulation zymogens with the Gla-EGF-EGF-SP domain struc-
ture (factor VII [FVII], FIX, FX, and protein C) in enhancing
hepatocyte transduction in vitro of both Ad5 and non-CAR
binding Ad5 (15) and for Ad5 capsids pseudotyped with fibers
from subgroup D Ad (14). Using a model system involving in
vivo warfarin pretreatment of mice to reduce circulating levels
of functional Gla domain-containing zymogens, we showed
that warfarin blocked the ability of a non-CAR binding Ad5
(AdKO1) to target the liver (15). Liver targeting was reconsti-
tuted by injection of physiological concentrations of FX 30 min
prior to virus injection, thereby confirming a particularly im-
portant role for FX. Because many studies have suggested that
CAR is redundant in Ad-mediated liver targeting, we sought to
assess the effect of coagulation zymogen depletion on liver
targeting mediated by Ad vectors with a nonmodified capsid
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FIG. 1. Schematic of the experimental design. MF1 outbred mice
were injected subcutaneously (S.C.) with 133 g of warfarin/mouse at
3 and 1 day prior to intravenous (I.V.) Ad injection (time zero). At 1
or 48 h postinjection, mice were perfused with phosphate-buffered
saline and livers were taken for assay of virion accumulation by quan-
titative PCR. Transgene levels were also evaluated at 48 h by -galac-
tosidase ELISA or by whole-body in vivo bioimaging for luciferase.
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(Ad5). We injected Ad5 vectors into MF-1 mice in the pres-
ence or absence of warfarin pretreatment (Fig. 1) and first
assessed transgene expression levels and then virion levels in
organs postinjection. In an assessment of transduction at 48 h
postinfection, a substantial reduction of liver targeting by war-
farin was observed (Fig. 2). Hence, taken with data on CAR
binding-deleted Ad vectors (15), this supports a redundancy of
the CAR pathway in hepatocyte transduction in vivo, previ-
FIG. 2. Assessment of liver targeting by CAR binding Ad5 and the influence of FX modulation. Mice were pretreated with warfarin or carrier
and injected with 4  1011 VP of Ad5/mouse with or without preinjection of FX at 30 min prior to virus injection. -Galactosidase levels were
quantitated by ELISA of the left lobe of the liver, spleen, and lungs. The median lobe of the liver was fixed in 70% ethanol before treatment with
5-bromo-4-chloro-3-indolyl--D-galactopyranoside for visualization of -galactosidase activity (inset). *, P  0.05 (as indicated) (Student’s t test);
n, 5/group; n.s., not significant.
FIG. 3. Effects of warfarin and FX on Ad5 virion accumulation. Ad5 vector (4  1011 VP/mouse) was injected into MF1 mice, and virion
accumulation was assessed by quantitative real-time PCR. Mice were sacrificed at 1 h or 48 h postinfection and perfused to exsanguination;
recovered DNA was subjected to real-time PCR (Applied Biosystems Prism 7900HT) and compared to standard curves generated from known
concentrations of virus. *, P  0.05 (versus controls) (Student’s t test); n, 5/group; ns, not significant.
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ously a controversial issue (4; reviewed in reference 11). Liver
transduction was fully restored by FX injection (Fig. 2). FX
injection resulted in physiological levels of circulating FX, con-
firmed by enzyme-linked immunosorbent assay (ELISA) (not
shown). Hence, warfarin-sensitive coagulation factors are fun-
damentally important in Ad5 liver transduction. Although, as
expected, Ad5 levels of transduction in the spleen were far
lower than in the liver, transduction was again substantially
reduced by the presence of warfarin and rescued by FX infu-
sion (Fig. 2). This suggests that binding of Ad5 to coagulation
factors also dictates Ad5 targeting to permissive cells in the
spleen. Levels in the lung were lower than in the liver and
spleen but were not significantly altered by warfarin or FX
infusion (Fig. 2).
We next sought to define early virion accumulation in liver
and spleen postinjection to ascertain whether warfarin could
block virion sequestration in addition to cell transduction.
Early Ad accumulation in liver and spleen is strongly associ-
ated with substantial targeting and clearance of Ad through
Kupffer cells, an effect that is acute (8, 10, 20). We therefore
assessed Ad virion levels at 1 h and 48 h postinfusion in the
warfarin pretreatment and FX rescue model using quantitative
Taqman PCR. Ad virion levels at 1 h postinjection were not
significantly different with warfarin treatment or FX reconsti-
tution from those in control mice (Fig. 3). This contrasted
sharply with the levels quantified at 48 h postinjection, which,
for the liver, paralleled transduction profiles (Fig. 3). This
observation suggests that coagulation zymogens do not affect
the substantial Kupffer cell uptake and supports the concept
that coagulation zymogens play a pivotal role selectively in trans-
duction of cells, both in the liver and in the spleen.
To confirm that the in vivo effects of warfarin are not limited
to Ad5, we assessed the effect on liver targeting of a fiber-
pseudotyped virus containing fibers from subgroup D (Ad5/
47). Previously, we showed in vitro that FX at physiological
concentrations promotes cell attachment and transduction of
FIG. 4. In vivo imaging and quantitation of the effects of warfarin on liver transduction by Ad5/5 and Ad5/47. Mice received warfarin or carrier
prior to intravenous Ad5/5 or Ad5/47. At 48 h, intraperitoneal injection of luciferin was followed by in vivo bioimaging with a Xenogen IVIS-50
cooled charge-coupled-device camera. Luciferase expression was quantitated as photon flux from the upper abdomen. *, P  0.05 (as indicated)
(Student’s t test).
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HepG2 hepatocytes mediated by a number of fiber-pseudotyped
vectors with fibers from subgroup D (14). We therefore in-
jected luciferase-expressing A5/47 into mice at 2  1010 virus
particles (VP) per mouse and assessed transgene expression by
bioluminescence at 48 h (Fig. 4). As shown, and in similarity to
injection of the control Ad5 vector expressing luciferase (6),
the liver infectivity of Ad5/47 was substantially reduced by
warfarin pretreatment (Fig. 4). Hence, the effect of coagula-
tion factors in vivo is relevant to Ad vectors with fibers derived
from subgroup D as well as from subgroup C (Ad5).
Combined with our previous studies (14, 15), we now show
that both CAR binding and non-CAR binding Ad vectors
predominantly utilize coagulation factors for liver and spleen
transduction in vivo, since warfarin substantially reduces trans-
duction of both viruses, an effect fully restored by FX infusion
at physiological levels. For Ad5, this suggests that CAR bind-
ing plays no role in liver targeting when delivered via the
bloodstream. This explains why many studies have shown no
effect of CAR binding mutants on in vivo Ad liver transduc-
tion. For vector retargeting strategies, however, it remains
unknown whether blocking of Ad-coagulation factor binding
will allow efficient retargeting of virus, since early virus accu-
mulation in the liver is not affected, at least for Ad5 (Fig. 3).
Hence, Kupffer cell-depleting or avoidance strategies may also
be required. Observations from this and previous studies, how-
ever, do provide evidence to suggest that blockade of coagu-
lation factor-mediated liver transduction by Ad may be a useful
approach for achieving transductional targeting. In the pres-
ence of a high-affinity retargeting strategy using bispecific an-
tibodies to retarget Ad to the angiotensin converting enzyme,
detectable transduction was achieved in target lung endothe-
lium; however, the majority of Ad still transduced the liver
(17). Transcriptional control was required to completely elim-
inate liver transgene expression (16). Clearly, in this paradigm,
assessing the effect of warfarin depletion of coagulation factors
on angiotensin converting enzyme-targeted Ad biodistribution
is warranted. Our experiments with Ad5/47 also highlight the
breadth of the effect that coagulation zymogens have on the
biology of different human Ad serotypes upon contact with
the bloodstream. In sum, our study defines the importance
of vitamin K-dependent coagulation zymogens on Ad5- and
Ad5/47-mediated liver transduction. It is likely that such
mechanisms are relevant in defining the in vivo infectivity of
many human Ad vectors being developed for gene-based
therapeutics.
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